Added to YB: 2026-02-16
Pitch date: 2025-12-05
CABA [bullish]
Cabaletta Bio, Inc.
+21.71%
current return
Author Info
No bio for this author
Company Info
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
Market Cap
$284.9M
Pitch Price
$2.58
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.96
P/E
-1.23
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Cabaletta Bio, Inc. - $CABA
CABA: CD19 CAR-T for autoimmune diseases. Kicking off pivotal myositis study (14pts, open-label, 16wk primary endpoint vs low registry benchmark). Phase1/2 DM pts hit TIS 60-90 off immunosuppression. No competition in myositis. 16-20k US pts, $250-300k pricing→$0.75-1.8B revenue. Additional upside in scleroderma & lupus. Chemo-free regimen in pemphigus validates safer approach. $160M cash into H2 2026. $250M mkt cap. BLA filing possible 2027 if pivotal succeeds.
Read full article (13 min)